The legal status of psilocybin mushrooms is changing rapidly across the United States. This guide covers what you need to know about federal law, state-level reform, and your responsibilities as a customer.
The question "are mushrooms legal?" does not have a single, straightforward answer. Psilocybin laws in the United States are evolving at a pace that few people anticipated even a decade ago. What was once treated as a uniformly prohibited substance is now the subject of voter-approved reforms, active clinical research, and meaningful legislative debate at both the state and local levels.
The result is a patchwork of regulations that varies significantly from one jurisdiction to the next. Some states have created legal frameworks for supervised psilocybin use, several cities have formally deprioritized enforcement, and the federal government has granted special research designations — all while the underlying federal classification remains unchanged. Understanding these distinctions is essential for anyone considering purchasing psilocybin products.
This page provides a factual overview of the current regulatory environment as we understand it. It is not legal advice. Drug laws are complex, jurisdiction-specific, and subject to change. We strongly encourage every customer to research the laws that apply in their own state and municipality and to consult a qualified attorney with any specific legal questions.
Under the Controlled Substances Act, psilocybin remains classified as a Schedule I substance at the federal level. Schedule I is reserved for compounds that the federal government considers to have high abuse potential and no currently accepted medical application. This places psilocybin in the same regulatory category as several other heavily restricted substances and means that, from a strictly federal standpoint, manufacturing, distributing, and possessing psilocybin carries legal risk. However, federal enforcement priorities and state-level reforms have created a more nuanced practical reality than the classification alone suggests.
Despite the Schedule I label, the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to psilocybin-assisted therapy for treatment-resistant depression. This designation is designed to fast-track the development and review of treatments that show substantial improvement over existing options. Major research universities and medical centers across the country are conducting clinical trials that explore psilocybin's potential for depression, PTSD, end-of-life anxiety, and substance use disorders. While this designation does not change psilocybin's current legal classification, it signals growing institutional recognition of its therapeutic value and may influence future rescheduling decisions.
It is important to understand the difference between decriminalization and legalization. Decriminalization means that enforcement of certain laws becomes the lowest priority for local authorities — it does not make psilocybin fully legal. Legalization, by contrast, would establish a regulated framework permitting production, sale, and use. Most progress in the United States so far falls under the decriminalization umbrella, though Oregon and Colorado have moved toward regulated access models.
Although federal law has not changed, a growing number of states and cities have acted independently to reform how psilocybin is regulated within their borders. These efforts range from making psilocybin-related offenses the lowest law enforcement priority to establishing fully regulated therapeutic access programs. The pace of reform has accelerated considerably in recent years, driven by public ballot initiatives, mounting scientific evidence, and shifting cultural attitudes toward psychedelic compounds.
In 2020, Oregon voters approved Measure 109, making it the first state to create a regulated framework for psilocybin-assisted therapy. The law established a licensing system for psilocybin service centers where adults can access psilocybin under the supervision of trained facilitators. Oregon also passed Measure 110, which broadly decriminalized personal possession of small amounts of controlled substances. Together, these measures represent the most comprehensive state-level approach to psilocybin access in the country and have served as a template for other jurisdictions considering similar reforms.
Colorado voters approved Proposition 122 — the Natural Medicine Health Act — in 2022. This ballot initiative decriminalized the personal use and possession of several naturally occurring psychedelic substances, including psilocybin, for adults 21 and older. It also directed the state to build a regulated access framework through licensed healing centers. Colorado's model draws on lessons from Oregon while reflecting the state's own regulatory priorities, and it continues to be refined through ongoing rulemaking processes.
A growing list of cities has passed resolutions that make the enforcement of laws against psilocybin possession the lowest priority for local police. Denver led the way in 2019, followed by Oakland and Santa Cruz in California with broader measures covering multiple naturally occurring psychedelics. Seattle, Washington, D.C., Ann Arbor, and several other municipalities have adopted similar deprioritization policies. While these local actions do not change state or federal law, they reflect shifting public attitudes and frequently serve as catalysts for wider legislative reform. Additional cities continue to introduce and vote on comparable measures each year.
Psilocybin regulations differ not only from state to state but sometimes from city to city within the same state. Before placing an order, take the time to look up the specific statutes and local ordinances that apply where you live. Municipal decriminalization does not override state or federal law, and the legal protections available to you depend entirely on your jurisdiction.
Even in areas where enforcement has been deprioritized, possession of psilocybin may still carry legal consequences under state or federal law. Decriminalization reduces the likelihood of prosecution, but it does not eliminate legal risk entirely. We encourage every customer to weigh these factors carefully, stay informed about any pending legislative changes in their area, and make decisions that align with their personal risk tolerance.
The legal landscape around psilocybin is changing rapidly. New ballot initiatives, legislative proposals, and regulatory frameworks are introduced on a regular basis. What is accurate today may not reflect the law six months from now. We recommend checking reputable news sources and advocacy organizations for the latest updates, and revisiting this page periodically as we update it to reflect major developments.
If you have specific questions about how psilocybin laws apply to your situation — whether related to employment, housing, travel, or personal use — the best course of action is to consult a licensed attorney in your state. Our team can point you toward general educational resources, but we are not qualified to provide legal counsel and nothing on this page should be treated as such.
My Mushroom Dispensary is committed to operating responsibly within the evolving regulatory environment. We believe that access to safe, lab-tested mushroom products should always be paired with honest education, full transparency, and genuine respect for the law. We do not encourage or condone any activity that violates applicable regulations.
Every batch of our microdose capsules and dried mushrooms undergoes rigorous third-party laboratory testing for potency, purity, and contaminant screening. We provide comprehensive educational resources — including free dosage guidance and ongoing customer support — so that each person who orders from us can make informed, responsible decisions about their wellness journey.
We actively monitor legislative and regulatory developments at the federal, state, and local levels and adjust our practices as needed. Our goal is to serve as a trusted resource not only for premium products but also for accurate, up-to-date information about psilocybin policy. When laws change, we update our operations and our informational materials accordingly.
We are encouraged by the growing body of clinical research that supports the therapeutic potential of psilocybin, and we believe this evidence will continue to drive meaningful reform. In the meantime, we ask every customer to take personal responsibility for understanding and complying with the laws in their area. Informed, intentional use benefits everyone — the individual, the community, and the broader movement toward sensible psychedelic policy.
Everything on this page is provided for general educational and informational purposes only. It does not constitute legal advice, and no attorney-client relationship is created by reading it. Laws governing psilocybin and other controlled substances vary significantly by jurisdiction and can change without notice.
My Mushroom Dispensary does not encourage or condone any activity that violates applicable law. If you need guidance on how psilocybin regulations apply in your specific location, we strongly recommend consulting a licensed attorney in your jurisdiction.
By using this website and purchasing our products, you acknowledge that you have independently reviewed the laws applicable in your area and that you accept full responsibility for complying with all relevant local, state, and federal regulations.
Browse our FAQ for answers on microdosing, strains, shipping, and more, or contact our team directly for direct help.
